DOI: https://doi.org/10.24959/ubphj.20.266

Clinical and economic analysis of pharmacotherapy of patients with toxic liver injury in Kharkiv hospitals

L. Iakovlieva, T. Bahlai

Abstract


Topicality. Currently, toxic liver lesions are widely spread in the world and in Ukraine, with various causes and chronic course.

Aim. To make clinical and economic analysis (ABC and frequency analysis) of pharmacotherapy of patients with toxic hepatitis based on hepatotropic drugs with ATC code A05A and A05B.

Materials and methods. The medical charts of 55 patients with the main diagnosis of “toxic hepatitis” from Kharkiv hospitals have been used.

Results and discussion. A total of 134 drugs have been used from different pharmacotherapeutic groups, administered 552 times, 10 appointments per patient, indicating polypharmacy. It was spent 254739,27 UAH for pharmacotherapy of 55 patients. Group A included 26 drugs, spent UAH 204035,91 (80.10 %), group B included 38 tonnes of drugs for the amount of UAH 38099,92 (14.96 %), and group C – 70 tonnes of drugs for the amount of UAH 12603,44 (4.94 %). Group A included the most expendable drugs, among which the first positions were mostly expensive drugs: Heptral (16 appointments), Heparizine (15), Ornilov (14), Hepadiff (9), sodium chloride solution 0.9 % (55, cheap drug) and other drugs.

Conclusions. Among the 134 drugs used for the pharmacotherapy of patients, 13 drugs of hepatotropic action and 5 drugs of amino acid composition with code A16AA, also used for the treatment of toxic hepatitis. The total amount of 128,875.88 UAH (50.59 %) has been spent for these 18 drugs, administered 272 times (49.28% of prescriptions).

Keywords


clinical and economic analysis; pharmacotherapy of patients; toxic hepatitis

References


Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of hepatology, 70 (1), 151–171. https://doi.org/10.1016/j.jhep.2018.09.014

Mao, W., Vu, H., Xie, Z., Chen, W., Tang, S. (2015). Systematic Review on Irrational Use of Medicines in China and Vietnam. PLoS ONE 10 (3), e0117710. https://doi.org/10.1371/journal.pone.0117710

Samootsinka naselenniam stanu zdorovia ta rivnia dostupnosti okremykh vydiv medychnoi dopomohy u 2018 rotsi. (2019). Derzhavna sluzhba statystyky. Available at: http://www.ukrstat.gov.ua/druk/publicat/kat_u/2019/ zb/03/zb_snsz2018pdf.pdf

Kleiner, D. E. (2017). Drug-induced Liver Injury: The Hepatic Pathologist’s Approach. Gastroenterology clinics of North America, 46 (2), 273–296. https://doi.org/10.1016/j.gtc.2017.01.004

Morozov, A. M., Yakovlieva, L. V., Bezditko, N. V. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno-profilaktychnomu zakladi (suprovid formuliarnoi systemy): metod. rek. Kharkiv, 36.


GOST Style Citations


1.  Burden of liver diseases in the world / S. K. Asrani, H. Devarbhavi, J. Eaton, P. S. Kamath // J. of Hepatol. – 2019. – Vol. 70 (1). – P. 151–171. https://doi.org/10.1016/j.jhep.2018.09.014

 

2.  Systematic Review on Irrational Use of Medicines in China and Vietnam / W. Mao, H. Vu, Z. Xie, W. Chen et al. // PLoS ONE. – 2015. – Vol. 10 (3). – e0117710. https://doi.org/10.1371/journal.pone.0117710.

 

3.  Самооцінка населенням стану здоров’я та рівня доступності окремих видів медичної допомоги у 2018 році. Державна служба статистики. – 2019. – 148 с. [Електронний ресурс]. – Режим доступу : http://www.ukrstat.gov.ua/druk/publicat/kat_u/2019/zb/03/ zb_snsz2018pdf.pdf (дата звернення: 29.01.2020).

 

4.  Kleiner, D. E. Drug-induced Liver Injury : The Hepatic Pathologist’s Approach / D. E. Kleiner // Gastroenterol. Clinics of North America. – 2017. – Vol. 46 (2). – P. 273–296. https://doi.org/10.1016/j.gtc.2017.01.004

 

5.  Оцінка клінічної та економічної доцільності використання лікарських засобів у лікувально-профілактичному закладі (супровід формулярної системи) : метод. рек. / А. М. Морозов, Л. В. Яковлєва, Н. В. Бездітко та ін. – Х., 2013. 36 с.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Ukr. biopharm. j.

ISSN 2519-8750 (Online), ISSN 2311-715X (Print)